Edition:
United Kingdom

Zealand Pharma A/S (ZEAL.OQ)

ZEAL.OQ on NASDAQ Stock Exchange Global Select Market

13.58USD
12 Dec 2017
Change (% chg)

$-0.26 (-1.88%)
Prev Close
$13.84
Open
$13.54
Day's High
$13.58
Day's Low
$13.28
Volume
11,208
Avg. Vol
--
52-wk High
$20.35
52-wk Low
$12.54

Select another date:

Thu, Dec 7 2017

BRIEF-Zealand Pharma Initiates Phase 3 Trial With Dasiglucagon

* ZEALAND PHARMA INITIATES THE PIVOTAL PHASE 3 TRIAL WITH DASIGLUCAGON FOR THE TREATMENT OF SEVERE HYPOGLYCEMIA IN DIABETES

BRIEF-Zealand Pharma Q3 operating loss at DKK 38.2 mln ​

* ‍MAINTAINS ITS REVENUE GUIDANCE OF A CONTINUED INCREASE IN ROYALTY PAYMENTS FROM SANOFI.​

BRIEF-Zealand reports royalty revenue Of DKK 10.3 mln for Q3

* REG- ZEALAND REPORTS ROYALTY REVENUE FOR THE THIRD QUARTER OF 2017

BRIEF-Zealand Pharma granted orphan drug designation by FDA

* REG-U.S. FDA GRANTS ORPHAN DRUG DESIGNATION TO GLEPAGLUTIDE FOR THE TREATMENT OF SHORT BOWEL SYNDROME

New Zealand forestry a first test in nationalist party's protectionist agenda

WELLINGTON Some New Zealand forest owners are suspending replanting of trees and re-thinking investments as the country's third-largest export earner finds itself in the sights of maverick politician Winston Peters' protectionist agenda.

BRIEF-Zealand Pharma to cooperate with Torrey Pines Institute for Molecular Studies

* REG-ZEALAND PHARMA AND TORREY PINES INSTITUTE FOR MOLECULAR STUDIES ANNOUNCE RESEARCH COLLABORATION

BRIEF-Zealand Pharma and Orbit Discovery enter into research collaboration

* REG-ZEALAND AND ORBIT DISCOVERY ENTER INTO RESEARCH COLLABORATION

BRIEF-Zealand Pharma to present at Morgan Stanley Global Healthcare Conference

* REG-ZEALAND PHARMA TO PRESENT AT MORGAN STANLEY GLOBAL HEALTHCARE CONFERENCE IN NEW YORK ON SEPTEMBER 12, 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Zealand Pharma Q2 operating loss widens to DKK 94.8 mln

* H1 REVENUE OF DKK 88.4 MILLION/USD 13.6 MILLION (DKK 14.7 MILLION/USD 2.2 MILLION IN FIRST HALF OF 2016)

BRIEF-Zealand Pharma partner starts Phase 1 trials for two novel treatments

* PHASE 1 TRIALS FOR TWO NOVEL TREATMENTS OF OBESITY AND/OR DIABETES INITIATED BY ZEALAND PARTNER BOEHRINGER INGELHEIM

Select another date: